Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6003 in Healthy Adult Volunteers

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.

Marburg hemorrhagic fever is a rare human disease caused by the Marburg virus, a filamentous, single-stranded, negative-sense RNA virus. In general, the mortality rate associated with Marburg virus outbreaks has ranged from 23% to 88%, with the highest death rates seen in more recent epidemics. No vaccine or effective therapy is available for Marburg hemorrhagic fever. AVI-6003 is an experimental combination of 2 phosphorodiamidate morpholino antisense oligomers with positive charges on selected subunits (PMOplus™). These oligomers specifically target viral messenger RNA encoding 2 Marburg virus proteins thought to be important in viral replication and host immune suppression. The present study is designed to characterize the safety, tolerability and pharmacokinetics of escalating single-administration doses of AVI-6003 in healthy human subjects.

Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)

Inclusion Criteria: Male or female and between the ages of 18 and 50 years in good general health Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential Volunteers must be willing to undergo a urine screen for drugs of abuse Exclusion Criteria: Pregnancy or breastfeeding. Any clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis Positive test for human immunodeficiency virus, hepatitis B or hepatitis C or known history of HIV infection